Bipolar Disorder

Massachusetts

33 Bipolar Disorder Trials near Massachusetts

Power is an online platform that helps thousands of Bipolar Disorder patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
Active on Power

ABX-002 for Bipolar Depression

Cromwell, Connecticut
The goal of this clinical trial is to learn if ABX-002 added to participants' existing treatment shows effects on brain chemistry that may relate to anti depressive effects This is a single treatment arm, open-label, Phase 2 study of ABX-002 in 30 adults with bipolar disorder and 5 healthy volunteers. Healthy volunteer participants will receive no drug treatment and will undergo 2 imaging sessions to confirm instrument and test - retest method reliability control. For bipolar disorder participants with depression, the study will include 3 study periods: 1. Screening Period of up to 4 weeks 2. 6-week Treatment Period 3. 2-week post dose Safety Follow-up Period. For healthy volunteers, the study will include 2 study periods: 1. Screening Period of up to 3 weeks 2. Imaging Period of up to 3 weeks.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

35 Participants Needed

KarXT for Mania

New Haven, Connecticut
The purpose of this study is to evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65

274 Participants Needed

Clozapine vs Risperidone for Psychosis

Boston, Massachusetts
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention. The study will utilize a stringent randomized, double-blinded, parallel group clinical trial design. B2 group will serve as psychosis control with risperidone as medication control. The study is designed to evaluate effect of clozapine on the B1 participants, and the effect that will be evaluated is a biomedical outcome. The study sample will be comprised of individuals with psychosis, including 1) schizophrenia, 2) schizoaffective disorder and 3) psychotic bipolar I disorder. The investigators plan to initially screen and recruit n=524 (from both the existing B-SNIP library and newly-identified psychosis cases, \~50% each) in order to enroll n=320 (B1 and B2) into the RCT.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 60

524 Participants Needed

Cannabidiol for Bipolar Disorder

Belmont, Massachusetts
Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar disorder who experience anxiety.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

25 Participants Needed

Focused Ultrasound for Bipolar Disorder

Boston, Massachusetts
The specific aim of this proposed study is to investigate the feasibility and therapeutic potential of transcranial focused ultrasound (tFUS) as a treatment for bipolar disorder (BD). Specifically, the investigators will study the effects of amygdala tFUS on corticolimbic activation during an emotion regulation task in BD, the effects of amygdala tFUS on corticolimbic resting-state functional connectivity in BD, and explore the relationship between tFUS-associated changes in amygdala activity and mood symptoms. The investigators hypothesize that transcranial focused ultrasound (tFUS) of the amygdala will be associated with decreased amygdala activation and increased ventromedial prefrontal cortex activation during a modified version of the Multi-Source Interference Task (MSIT) paired with affective pictures from the International Affective Picture System (IAPS). The investigators also hypothesize that tFUS of the amygdala will be associated with increased resting-state functional connectivity between the amygdala and ventromedial prefrontal cortex. Finally, the investigators hypothesize that tFUS-associated reductions in amygdala activity could be positively correlated with reductions in depressive symptom scores and global improvement.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 64

20 Participants Needed

Future Thinking Intervention for Smoking and Bipolar Disorder

Boston, Massachusetts
Future Self-BD is a 6-session virtual intervention that encourages participants to vividly generate personal and positive future events that they anticipate may be benefited by smoking cessation. Each session will be conducted on HIPAA-compliant Zoom and led by the PI (Dr. Gold).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

70 Participants Needed

Ketosis for Bipolar Disorder

Charlestown, Massachusetts
The goal of this clinical trial is to test how specific components of diet affect brain function and behavior for individuals with bipolar. The main question it aims to answer is how glucose and ketones each affect the brain's response to risk and reward. Participants will be asked to provide blood (to assess baseline measures of how the body uses energy), and then to receive two MRI scan sessions, on separate days. During each MRI scan session, participants will play three games, from which they can win money, before and after drinking glucose (on one day) or ketones (on the other day). Investigators will compare individuals with and without bipolar to test whether the two groups differ in how their brains use energy, and to test how the brain's use of energy affects behavior.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45

100 Participants Needed

iTBS-TMS for Bipolar Disorder

Charlestown, Massachusetts
The objective of this study protocol is to test whether intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) can strengthen functional connectivity with a key region in emotion regulation (ER) neurocircuitry (anterior insula, AI) and improve performance on ER-related tasks in patients with bipolar disorder. Individual IPL sites for stimulation will be identified through baseline, pre-TMS functional magnetic resonance imaging (fMRI) scans. Patient-specific IPL subregions showing positive functional connectivity with the anterior insula and falling within the patient-specific frontoparietal control network will be used as individualized target sites for TMS stimulation. Patients will be randomized to receive 24 sessions of active versus sham iTBS to patient-specific IPL targets (6 sessions/day, 4 days, 43,200 pulses total). Post-iTBS resting-state and task-based fMRI scans will be acquired 3 days after the final day of iTBS administration (Day 4) following identical procedures as baseline. Effects of iTBS-TMS on ER will be evaluated by comparing pre-TMS versus post-TMS functional connectivity and behavior during performance on ER tasks.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:24 - 65

136 Participants Needed

Transcranial Magnetic Stimulation for Bipolar Disorder

Charlestown, Massachusetts
The investigators are conducting this research study to better understand how individuals with bipolar disorder regulate their emotions, and if transcranial magnetic stimulation (TMS) can help improve emotion regulation for individuals with bipolar mood disorders.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 55

60 Participants Needed

ITAP + SAFE for Bipolar and Substance Use Disorders

Providence, Rhode Island
This trial tests two different approaches for helping people with both bipolar disorder and substance use problems. One group gets a special support program with therapy and activities, while the other group gets extra safety check-ins. Both groups continue their usual care.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

160 Participants Needed

Magnetic Stimulation for Bipolar Depression

Belmont, Massachusetts
The protocol involves functional Magnetic Resonance Imaging acquisitions immediately before and after Low Field Magnetic Stimulation treatment on two separate days in a sham controlled, randomized trial, in order to assess the physiologic effects of Low Field Magnetic Stimulation on brain function in a geriatric population with bipolar depression.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:50+

40 Participants Needed

Ketogenic Diet for Mental Illness

Belmont, Massachusetts
This is a 12-week open-label extension study for participants completing study NCT06221852.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:18 - 45

50 Participants Needed

TMS for Bipolar Mood Disorders

Charlestown, Massachusetts
This trial is testing if using magnetic fields to stimulate brain cells can help people with bipolar disorder manage their emotions better. Current treatments often don't work well for these patients, so this new approach aims to improve their emotional control by targeting specific brain areas.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 55

15 Participants Needed

Deep Brain Stimulation for Bipolar Disorder

Boston, Massachusetts
This study is only enrolling at Baylor College of Medicine. The other research locations listed serve to support data analysis only. This research study is to investigate the use of technology called Deep Brain Stimulation (DBS) to potentially improve Treatment-Resistant Bipolar Depression (TRBD) symptoms in patients with severe cases. DBS involves the surgical implantation of leads and electrodes into specific areas of the brain, which are thought to influence the disease. A pack implanted in the chest, called the neurotransmitter, keeps the electrical current coursing to the brain through a wire that connects the neurotransmitter and electrodes. It is believed DBS may restore balance to dysfunctional brain circuitry implicated in TRBD. The goal of this study is to enhance current approaches to DBS targeting in the brain and to use a novel approach to find a better and more reliable system for TRBD treatment. Its important for participants to understand that this is an investigational study where there could be a lack of effectiveness in improving TRBD symptoms. There may be no directly benefit from taking part in this study. This study is expected to last 20 months and involves 3 main steps. 1. Medical, psychiatric, and cognitive evaluations. 2. Implantation of a brain stimulation system. 3. Follow up after implantation of device, including programming, recording, and psychiatric testing. There are risks and benefits to this study which need to be considered when deciding to participate or not. Some of the risks are from surgery, the DBS device and programming, the tests involved, and potential loss of confidentiality, as well as other unknown risks. Some of the more serious risks involved in this study and the percentage that they occur: 1. Bleeding inside the Brain (1 to 2 percent). 2. Infection from the procedures (3 percent) 3. Seizure caused from the procedures (1.2 percent) However, the benefit of this study is that it may help relieve or decrease TRBD symptoms. This form of treatment has shown to reduce symptom severity in other cases. This could potentially improve quality of life and activities in daily routines. There is also a potential benefit to society in that the data the investigators will obtain from this study may help increase the understanding of the mechanisms underlying TRBD symptoms, as well as enhanced Deep Brain Stimulation techniques. Study participation is expected to last 20 months from the time the DBS device is activated and should include approximately 23 visits. These visits also include 8 separate, 24 hour stays at the Menninger NeuroBehvaioral Monitoring Unit (NBU). These 24-hour sessions will occur at multiple points throughout the study (1 week prior to surgery, the week preceding device activation, the week following activation, then after 2 weeks, 4 weeks, 6 months, 9 months, and 12 months). Participants will need to stay locally for the week of the NBU stay (typically Monday through Friday). Study visits will include clinician administered assessments and questionnaires, subject reported assessments, neuropsychological testing, and mobile behavioral assessments which will occur around 23 visits over the course of 20 months.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:22 - 64

10 Participants Needed

OLZ/SAM for Schizophrenia

Hartford, Connecticut
This trial evaluates the safety and tolerability of OLZ/SAM in children and adolescents with schizophrenia or Bipolar I disorder. OLZ/SAM combines olanzapine to manage symptoms and samidorphan to reduce weight gain. Olanzapine is a well-established antipsychotic effective for schizophrenia and bipolar I disorder, but its use is limited by significant weight gain; samidorphan is added to mitigate this side effect.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:10 - 17

236 Participants Needed

Multiple Medications for Bipolar Depression

Boston, Massachusetts
This trial is testing four different medications to find the best treatment for adults with bipolar disorder type 1 who are currently depressed. The medications work by balancing brain chemicals that affect mood. The goal is to help patients recover from depression and stay well.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 4

2726 Participants Needed

Magnesium + Vitamin B6 for Bipolar Disorder

Belmont, Massachusetts
This trial tests a mix of magnesium and vitamin B6 supplements for patients who have recently experienced their first episode of bipolar I disorder. The treatment aims to improve mood and reduce anxiety by supporting brain energy production and function.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 50

40 Participants Needed

Perampanel + Ketamine for Suicidal Thoughts

West Haven, Connecticut
The purpose of this study is to test the hypothesis that the anti-depressant and anti-suicidal effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist Ketamine is critically dependent on stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid receptors (AMPAR).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:21 - 65

30 Participants Needed

Mindfulness-Based Therapy for Serious Mental Illness

Providence, Rhode Island
Serious mental illness (SMI), encompassing schizophrenia-spectrum and major mood disorders, has been estimated to affect approximately 5.4% of the U.S. adult population each year. Research shows low rates of evidence-based treatment being provided to patients with SMI. This is unfortunate, because evidence-based psychological therapies have been shown to be effective for improving outcomes in SMI. One such efficacious psychological intervention is mindfulness-based therapy (MBT), which integrates mindfulness practice with cognitive-behavioral strategies to improve illness management. Previous trials conducted in the United Kingdom have shown that MBT improves symptoms and functioning in community-based outpatients with SMI, including in routine practice settings. In the U.S., most patients with SMI receive treatment at local community mental health centers (CMHCs). However, patients in CMHCs often cannot access evidence-based therapies like MBT due to the lack of trained staff able to provide these interventions. Further, previous studies of MBT have been conducted exclusively outside the U.S. It is essential to confirm that MBT is effective when delivered for patients with SMI in the U.S., and how it can be sustainably implemented in CMHCs where this clinical population is commonly treated. Thus, the investigators propose to test the effectiveness of MBT for SMI and study its implementation in a typical CMHC setting. The investigators will randomize 160 patients with SMI (psychotic-spectrum and major mood disorders) to receive treatment as usual (TAU) vs TAU plus MBT delivered by frontline clinicians in a large, diverse CMHC. The investigators will conduct blinded assessments at baseline and at 6- (mid), 12- (post), and 24-weeks (follow-up). Consistent with an experimental therapeutics approach, the investigators will examine potential mechanisms of action (e.g., mindfulness skills), as well as collect implementation-focused quantitative and qualitative data from our community partners (patients, administrators, clinicians). If found to be effective and aided by a certified training program and the implementation data collected, MBT could be adopted as a future evidence-based practice and integrated into the routine community care of patients with SMI, thereby reducing health disparities.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

160 Participants Needed

mHealth Intervention for Severe Mental Illness

Providence, Rhode Island
The overall aim of this program of research is to improve the continuity of care for patients with serious mental illness (SMI) by supporting a safer and more efficient bridge from hospital to outpatient care using a mobile device-delivered app called Transition-FOCUS (tFOCUS), which has previously been tested in community samples. The purpose of the proposed project is to establish the effectiveness of our empirically-supported, multi-component mHealth intervention.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

180 Participants Needed

Why Other Patients Applied

"I've been experiencing bipolar depression since I was a teenager and have tried many treatments that have not helped: SSRIs (Prozac), Wellbutrin, talk therapy. None worked. I've heard great things about ketamine therapy and would really like to try it. I'd like to access it through a clinical trial."

FM
Bipolar Disorder PatientAge: 38

"I really would love to be normal. A functioning part of society. It is very hard to hold a job with this condition. I need to be steady. I do NOT like my current meds or ones I've tried before, so new therapies are of interest to me. "

EC
Bipolar Disorder PatientAge: 42

"Over 20 years, I've tried 6+ antidepressants and anti-anxiety meds to no avail. Cymbalta is the ONLY one that has ever made a difference (which I can use because I have bipolar 2, not 1) but it had some other side effects. I've been hesitant to try any trials, but also at a deadend of any relief. So, let's give it a shot."

ZJ
Bipolar Disorder PatientAge: 42

"I have struggled living with bipolar disorder for nearly 20 years. I am always hopeful to find new treatments or medications that might really help my symptoms, and I feel strongly pulled to help contribute to bipolar research/science any way that I can. Finally use this brain for some good! :)"

PC
Bipolar Disorder PatientAge: 40

"My mania is under control but I still have no way of handling depression. I've been looking into new treatments and I would be so grateful to be able to try one of the latest research treatments. Even if it fails: it's worth a shot, better than giving up. I'm a bit at wit's end."

PW
Bipolar Disorder PatientAge: 30

Enhanced Care for Psychosis

Worcester, Massachusetts
The goal of this clinical trial is to compare engagement in treatment in coordinated specialty care (CSC) to five extra care elements (CSC 2.0) in first-episode psychosis. The main question it aims to answer is: • Does the addition of certain elements of care increase the number of visits in treatment for first-episode psychosis? Participants will either: * Receive care as usual (CSC) or * Receive care as usual (CSC) plus five additional care elements (CSC 2.0): 1. Individual peer support 2. Digital outreach 3. Care coordination 4. Multi-family group therapy 5. Cognitive remediation Researchers will compare the standard of care (CSC) to CSC 2.0 to see if participants receiving CSC 2.0 have more visits to their clinic in their first year.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

350 Participants Needed

Xenon Inhalation Therapy for Depression

Boston, Massachusetts
The investigators will test the hypothesis that inhaled xenon will produce a rapid improvement in depressive symptoms in patients suffering from treatment-resistant depression. Specifically, the investigators will conduct a parallel randomized, double-blind crossover study that will compare the effects of xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group) to the effects of nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group). A total of 20 severely depressed patients, 10 with major depressive disorder (MDD) and 10 with Bipolar Depression (BP), will be exposed in random order to N-TAU and X-TAU in a double-blind protocol.

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 65

20 Participants Needed

Ketogenic Diet for Bipolar Disorder

Belmont, Massachusetts
This is a randomized, controlled clinical trial to assess the effects of the ketogenic diet in combination with treatment as usual on brain energy metabolism and psychiatric symptoms in individuals with first episode bipolar disorder and schizoaffective disorder.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45

50 Participants Needed

Lurasidone for Cognitive Improvement in Bipolar Disorder

Boston, Massachusetts
This trial is testing whether lurasidone can help improve thinking and memory in people with bipolar disorder who are currently stable but have cognitive problems. The medication works by balancing brain chemicals. Lurasidone has shown potential in improving thinking and memory in both schizophrenia and bipolar disorder.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Age:19 - 65

150 Participants Needed

ITAP-VA for Bipolar and Substance Use Disorders

Providence, Rhode Island
This trial tests a special program and extra safety checks for Veterans with bipolar disorder and substance use issues. The goal is to help them stick to their treatment plans and ensure their safety after leaving the hospital.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

140 Participants Needed

Psychobehavioral Intervention for Reducing Suicide Risk

New Haven, Connecticut
The purpose of this study is to advance a non-pharmacologic suicide preventive intervention with wide dissemination potential as an innovative high-yield solution to reduce suicide rates. The investigators aim to achieve this with this study of Brain Emotion Circuitry Self-Monitoring and Regulation Therapy for Daily Rhythms (BE-SMART-DR), that provides self-directed strategies to regularize sleep and other DRs to reduce short-term suicide risk that can be used lifelong to potentially also reduce long-term suicide risk.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:16 - 29

128 Participants Needed

Magnetic Stimulation for Psychosis

Boston, Massachusetts
The goal of this clinical trial is to learn about cognition in psychotic disorders (schizophrenia, bipolar disorder, and schizoaffective disorder). The main question it aims to answer is: Can we use magnetic stimulation to change processing speed (how quickly people can solve challenging tasks). Participants will be asked to perform cognitive tasks (problem-solving) and undergo brain scans before and after transcranial magnetic stimulation (TMS). TMS is a way to non-invasively change brain activity. Forms of TMS are FDA-approved to treat depression and obsessive compulsive disorder. In this study, we will use a different form of TMS to temporarily change brain activity to observe how that changes speed in problem-solving.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 55

95 Participants Needed

Glutamate Imaging and Cognitive Testing for Depression

New Haven, Connecticut
This research study is designed to look at the involvement of the glutamate system in depression. Each subject will undergo a screening appointment to determine study eligibility. Thereafter, the study will take 2 or 3 visits depending on schedule availability and will consist of one MRI scan, and PET scan. Subjects will also participate in cognitive testing. Depending on camera time, staff availability and subject schedule, total study participation may last 1-2 months.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

180 Participants Needed

Transcranial Electrical Stimulation for Bipolar Disorder

Boston, Massachusetts
Mania is a core symptom of bipolar disorder involving periods of euphoria. Decreased inhibitory control, increased risk-taking behaviors, and aberrant reward processing are some of the more recognized symptoms of bipolar disorder and are included in the diagnostic criteria for mania. Current drug therapies for mania are frequently intolerable, ineffective, and carry significant risk for side effects. Presently there are no neurobiologically informed therapies that treat or prevent mania. However, using a newly validated technique termed lesion network mapping, researchers demonstrated that focal brain lesions having a causal role in the development of mania in people without a psychiatric history can occur in different brain locations, such as the right orbitofrontal cortex (OFC), right dorsolateral prefrontal cortex (DLPFC), and right inferior temporal gyrus (ITG). This lesion network evidence converges with existing cross-sectional and longitudinal observations in bipolar mania that have identified specific disruptions in network communication between the amygdala and ventro-lateral prefrontal cortex. The OFC is associated with inhibitory control, risk-taking behavior, and reward learning which are major components of bipolar mania. Thus, the association between OFC with mania symptoms, inhibitory control, risk-taking behavior, and reward processing suggests that this region could be targeted using non-invasive brain stimulation.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 65

24 Participants Needed

CRAFT-EP for Psychosis and Substance Use

Belmont, Massachusetts
The purpose of this study is to evaluate Community Reinforcement and Family Training for Early Psychosis (CRAFT-EP) for families experiencing early psychosis and substance use delivered exclusively or primarily via telehealth (video conferencing).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

80 Participants Needed

12

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Bipolar Disorder clinical trials in Massachusetts pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Bipolar Disorder clinical trials in Massachusetts work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Bipolar Disorder trials in Massachusetts 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Massachusetts for Bipolar Disorder is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Massachusetts several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Bipolar Disorder medical study in Massachusetts?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Bipolar Disorder clinical trials in Massachusetts?

Most recently, we added Home-Based Exercise for Serious Mental Illness, Mindfulness-Based Therapy for Serious Mental Illness and KarXT for Mania to the Power online platform.

Is there hope for people with bipolar?

Absolutely—bipolar disorder is very treatable: with mood-stabilizing medicines plus evidence-based talk therapy and a regular sleep–wake routine, more than 70 % of people achieve long symptom-free stretches and many return to work, school, and satisfying relationships. Sticking with treatment, watching for early warning signs, and using supports such as the Depression & Bipolar Support Alliance greatly increase those odds, so a full, meaningful life is a realistic goal rather than wishful thinking.

What is the first red flag of bipolar disorder?

There isn’t one universal “first” symptom, but the earliest red flag doctors see most often is a sudden decrease in the need for sleep—sleeping only a few hours yet feeling unusually energized and unable to shut your mind off. If this change lasts several days, especially when paired with racing thoughts, extra talkativeness, big ideas, or risky spending, it’s time to get a mental-health check-up because catching bipolar disorder early greatly improves treatment success.

What is the strongest medication for bipolar?

There isn’t a single “strongest” pill for bipolar disorder; doctors match the medicine to the phase and the person. For acute mania, lithium or valproate often combined with an atypical antipsychotic (e.g., quetiapine, olanzapine) typically works fastest; for bipolar depression, lamotrigine or quetiapine lead, and for long-term prevention lithium remains the gold standard when tolerated. The best regimen is the one that controls your symptoms with acceptable side effects, so choice and dose are always individualized by a psychiatrist who can monitor blood levels and overall health.

Why do people with bipolar go off their meds?

People stop bipolar medication for three main clusters of reasons: 1) medication factors—unpleasant side-effects (weight gain, tremor, mental “fog”) or complex dosing that make daily use feel worse than the illness; 2) illness factors—mood swings that create denial (“I’m fine now”) or the euphoric energy of mania that makes pills seem unnecessary or even unwanted; and 3) practical/social factors—cost, stigma, substance use, or a poor fit with the prescribing clinician. Recognizing which cluster is at play helps patients, families, and doctors tailor solutions—whether that’s adjusting the drug, adding psycho-education or reminders, or improving access—rather than assuming the person is simply being “non-compliant.”

What is unhealthy coping for bipolar people?

With bipolar disorder, “unhealthy coping” is anything you do to feel better in the moment that ends up disrupting one of three stabilisers: (1) your medication plan, (2) a regular sleep-and-daily routine, or (3) clear, substance-free judgement. Habits that break those stabilisers—skipping meds, drinking or using drugs, staying up late gaming or doom-scrolling, isolating yourself, or chasing risky thrills like overspending—tend to push mood swings harder and make recovery slower; replacing them with steady sleep, sober living, social support, and professional treatment keeps the illness on a shorter, safer leash.

Can untreated bipolar disorder lead to psychosis?

Yes. When bipolar mood swings are allowed to build unchecked, they can become so intense that a person loses touch with reality—research shows psychosis occurs in roughly 6 in 10 people with bipolar I and 2 in 10 with bipolar II, usually during extreme mania or depression. Staying on mood-stabilizing medication, keeping a regular sleep schedule, and seeking immediate care if hallucinations or fixed false beliefs emerge greatly reduce this risk and shorten episodes.

How does a person with bipolar think?

Thinking in bipolar disorder depends on the phase: during mania the mind races with big, fast ideas and bold confidence, while during depression thoughts slow down, dwell on negatives, and decision-making feels heavy; between episodes most people return to their usual, clear thinking, though some lingering trouble with focus or memory can remain. Recognising these predictable swings—and getting help early with medication, therapy, sleep, and support—makes it easier to manage symptoms and respond to a loved one with understanding instead of frustration.

Which hormone causes bipolar disorder?

No single hormone causes bipolar disorder; it is a brain-based mood condition shaped by genetics, life stress, and how different body systems interact. Shifts in thyroid hormone, the stress hormone cortisol, or female sex hormones can nudge symptoms better or worse—which is why doctors often check thyroid levels and watch times like postpartum or menopause—but fixing those levels alone doesn’t cure the disorder.

What is end stage bipolar disorder?

“End-stage” (or late-stage) bipolar disorder is an informal term doctors sometimes use for people whose illness has become chronic, treatment-resistant, and functionally disabling: mood swings remain frequent or severe despite multiple therapies, and there may be memory problems, physical health issues, and difficulty living independently. While this stage signals a need for more intensive care—such as combination medications, electro-convulsive or other neuromodulation therapies, cognitive/functional rehabilitation, and strong social supports—it is not a hopeless diagnosis; working closely with a mental-health team can still reduce symptoms and improve quality of life.

What current research is being done for bipolar disorders?

Today’s bipolar-disorder research falls into five main streams: scientists are mapping hundreds of risk and “treatment-response” genes, testing rapid-acting medicines such as ketamine and psilocybin, refining brain-stimulation tools like transcranial magnetic stimulation, using smartphone and wearable data to predict mood swings and stabilize sleep-wake cycles, and running early-intervention trials in high-risk teens and young adults. Together, these projects aim not just to explain why bipolar illness occurs but to deliver faster, more personalized treatments and even prevent new episodes before they start.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

Top Clinical Trials near Granger, IN

Top Clinical Trials near Bronx, NY

Top Dbs Clinical Trials

133 Clinical Trials near Dearborn Heights, MI

Top Clinical Trials near Canandaigua, NY

Top Ewing Sarcoma Clinical Trials

Top Clinical Trials near Hanover, NH

58 Clinical Trials near Wisconsin

Top Clinical Trials near Des Plaines, IL

Top Neurofibromatosis Clinical Trials

Top Clinical Trials near Fort Belvoir, VA

22 Bipolar Disorder Trials near Los Angeles, CA

By Trial

89Zr-DFO-YS5 Imaging for Prostate Cancer

Mastering the World of Work for Mental Illness

Ribociclib + Everolimus for Brain Tumors

Empagliflozin + Potassium Nitrate for Heart Failure

Beetroot Juice for Sleep Quality in Healthy Subjects

Surgery, Radiation & Chemotherapy for Early-Stage Hodgkin's Lymphoma

Atezolizumab + Trastuzumab Emtansine for Breast Cancer

Client-Centered Care Coordination for HIV Prevention

Ublituximab for Multiple Sclerosis

BGB-21447 for Non-Hodgkin's Lymphoma

Selinexor + Pomalidomide + Dexamethasone ± Carfilzomib for Multiple Myeloma

Paclitaxel Coated Balloon for Bowel Stricture

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial